Recent Quotes

My Watchlist

Indicators

Markets:

Overview

News

Currencies

International

Treasuries

Apogee Therapeutics, Inc. - Common Stock (NQ:APGE)

80.27 -1.88 (-2.28%)

Streaming Delayed Price Updated: 10:19 AM EDT, Jun 1, 2026 Add to My Watchlist

Price and Volume

Detailed Quote

Volume	64,139
Open	80.12
Bid (Size)	79.87 (100)
Ask (Size)	80.54 (200)
Prev. Close	82.14
Today's Range	79.88 - 81.99
52wk Range	34.34 - 95.30
Shares Outstanding	56,367,802
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News

Apogee Therapeutics to Participate in Upcoming June Conferences

May 28, 2026

From Apogee Therapeutics

Via GlobeNewswire

Apogee Therapeutics Announces $1.3 Billion Strategic Financing Collaboration with Blackstone Life Sciences to Advance Phase 3 Development and Commercialization of Zumilokibart

May 27, 2026

From Apogee Therapeutics

Via GlobeNewswire

Performance

YTD	+5.9%	+5.9%
1 Month	-0.6%	-0.6%
3 Month	+13.2%	+13.2%
6 Month	+16.4%	+16.4%
1 Year	+120.9%	+120.9%

More News

Apogee Therapeutics Announces Positive 16-Week Part B Induction Dose Optimization Results from Phase 2 APEX Trial of Zumilokibart in Moderate-to-Severe Atopic Dermatitis

May 27, 2026

From Apogee Therapeutics

Via GlobeNewswire

Apogee Therapeutics to Host Conference Call to Report Part B 16-Week Data from the Phase 2 APEX Trial of Zumilokibart in Patients with Moderate-to-Severe Atopic Dermatitis on May 27, 2026

May 26, 2026

From Apogee Therapeutics

Via GlobeNewswire

Apogee Therapeutics (NASDAQ:APGE) Beats Q1 Estimates with Strong Cash Runway and Promising Clinical Progress ↗

May 11, 2026

Via Chartmill

Apogee Therapeutics (NASDAQ:APGE) Reports Q4 2025 Results, Highlights Cash Runway and Key 2026 Clinical Catalysts ↗

March 02, 2026

Via Chartmill

Apogee Therapeutics Provides Pipeline Progress and Reports First Quarter 2026 Financial Results

May 11, 2026

From Apogee Therapeutics

Via GlobeNewswire

Eli Lilly Shares Slip Despite Positive Eczema Trial Results: Why the Market Reacted Coolly

March 27, 2026

Via MarketMinute

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $403 Million

March 26, 2026

From Apogee Therapeutics

Via GlobeNewswire

Apogee CEO Sells 20,000 Shares as Stock Surges Nearly 100% in a Year, but Here's What Really Matters for Investors ↗

March 26, 2026

Via The Motley Fool

Apogee Therapeutics, Inc. Announces Pricing of $350 Million Underwritten Public Offering

March 24, 2026

From Apogee Therapeutics

Via GlobeNewswire

Apogee Therapeutics, Inc. Announces Proposed $300 Million Underwritten Public Offering

March 23, 2026

From Apogee Therapeutics

Via GlobeNewswire

Small-Cap Resilience: Russell 2000 Surges 3% as Geopolitical Tensions Ease and ‘Risk-On’ Appetite Returns

March 23, 2026

Via MarketMinute

Gapping stocks in Monday's session ↗

March 23, 2026

Via Chartmill

Wondering what's happening in today's pre-market session? ↗

March 23, 2026

Via Chartmill

Apogee Therapeutics Announces Positive Phase 2 Part A 52-Week Data of Zumilokibart (APG777), Demonstrating Maintenance and Deepening of Responses with Every 3- and 6-Month Dosing in Moderate-to-Severe Atopic Dermatitis

March 23, 2026

From Apogee Therapeutics

Via GlobeNewswire

Apogee Therapeutics to Host Conference Call to Report Part A 52-Week Data from the Phase 2 APEX Trial of Zumilokibart (APG777) in Patients with Moderate-to-Severe Atopic Dermatitis on March 23, 2026

March 22, 2026

From Apogee Therapeutics

Via GlobeNewswire

Signal or Noise: What VR Adviser's Spyre Theraputics Buy Means for Fools ↗

March 18, 2026

Via The Motley Fool

What to Make of VR Adviser's Big Ocular Therapeutix Sell-Down ↗

March 18, 2026

Via The Motley Fool

VR Adviser Adds Over 1 Million Savara Shares ↗

March 15, 2026

Via The Motley Fool

Investment Manager Fully Exits Immunome Stock in $37.3 Million Sale, According to Latest SEC Filing ↗

March 04, 2026

Via The Motley Fool

Investment Manager Sells $5.1 Million Worth of LQDA Stock, According to Recent SEC Filing ↗

March 04, 2026

Via The Motley Fool

Apogee Therapeutics Provides Pipeline Progress and Reports Full Year 2025 Financial Results

March 02, 2026

From Apogee Therapeutics

Via GlobeNewswire

Apogee Therapeutics Stock Up 100% as Fund Lifts Stake to $28 Million ↗

February 25, 2026

Via The Motley Fool

This Fund Bet $20 Million on RAPT Therapeutics as Stock Surges 500% This Past Year and Buyout Offer Emerges ↗

February 25, 2026

Via The Motley Fool

Frequently Asked Questions

Is Apogee Therapeutics, Inc. - Common Stock publicly traded?

Yes, Apogee Therapeutics, Inc. - Common Stock is publicly traded.

What exchange does Apogee Therapeutics, Inc. - Common Stock trade on?

Apogee Therapeutics, Inc. - Common Stock trades on the Nasdaq Stock Market

What is the ticker symbol for Apogee Therapeutics, Inc. - Common Stock?

The ticker symbol for Apogee Therapeutics, Inc. - Common Stock is APGE on the Nasdaq Stock Market

What is the current price of Apogee Therapeutics, Inc. - Common Stock?

The current price of Apogee Therapeutics, Inc. - Common Stock is 80.27

When was Apogee Therapeutics, Inc. - Common Stock last traded?

The last trade of Apogee Therapeutics, Inc. - Common Stock was at 06/01/26 10:19 AM ET

What is the market capitalization of Apogee Therapeutics, Inc. - Common Stock?

The market capitalization of Apogee Therapeutics, Inc. - Common Stock is 4.52B

How many shares of Apogee Therapeutics, Inc. - Common Stock are outstanding?

Apogee Therapeutics, Inc. - Common Stock has 5B shares outstanding.

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.